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A B S T R A C T
Background
Glutamine is a conditionally essential amino acid. Endogenous biosynthesis may be insufﬁcient for tissue needs in states of metabolic
stress. Evidence exists that glutamine supplementation improves clinical outcomes in critically ill adults. It has been suggested that
glutamine supplementation may also beneﬁt preterm infants.
Objectives
To determine the effects of glutamine supplementation on mortality and morbidity in preterm infants.
Search methods
We used the standard search strategy of the Cochrane Neonatal Review Group. This included searches of the Cochrane Central
Register of Controlled Trials (CENTRAL, 2015, Issue 12), MEDLINE, EMBASE andMaternity and Infant Care (to December 2015),
conference proceedings and previous reviews.
Selection criteria
Randomised or quasi-randomised controlled trials that compared glutamine supplementation versus no glutamine supplementation in
preterm infants at any time from birth to discharge from hospital.
Data collection and analysis
We extracted data using the standard methods of the Cochrane Neonatal Review Group, with separate evaluation of trial quality and
data extraction by two review authors. We synthesised data using a ﬁxed-effect model and reported typical relative risk, typical risk
difference and weighted mean difference.
Main results
We identiﬁed 12 randomised controlled trials in which a total of 2877 preterm infants participated. Six trials assessed enteral glutamine
supplementation and six trials assessed parenteral glutamine supplementation. The trials were generally of good methodological quality.
Meta-analysis did not ﬁnd an effect of glutamine supplementation on mortality (typical relative risk 0.97, 95% conﬁdence interval 0.80
to 1.17; risk difference 0.00, 95% conﬁdence interval -0.03 to 0.02) or major neonatal morbidities including the incidence of invasive
infection or necrotising enterocolitis. Three trials that assessed neurodevelopmental outcomes in children aged 18 to 24 months and
beyond did not ﬁnd any effects.
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Authors’ conclusions
The available trial data do not provide evidence that glutamine supplementation confers important beneﬁts for preterm infants.
P L A I N L A N G U A G E S U M M A R Y
Glutamine supplementation to prevent morbidity and mortality in preterm infants
Review question: In preterm infants, does glutamine supplementation reduce the risk of death or disability?
Background:Glutamine is an important nutrient for growth and development and may be especially important in protecting preterm
infants from infections and gut problems that cause death and disability. We sought evidence that giving preterm infants extra glutamine
improves important outcomes.
Study characteristics: We found 12 randomised controlled trials (enrolling 2877 infants in total). The trials were generally of good
methodological quality.
Key results: These trials did not provide strong or consistent evidence that glutamine supplementation affected the risk of death,
serious infection or bowel disease, or longer term development.
Conclusions: Glutamine supplementation is not likely to be beneﬁcial for preterm infants.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Population: Preterm infants
Intervention: Glutamine supplementat ion ¶
Comparison: No supplementat ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Risk with no supplementa-
tion
Risk with Glutamine sup-
plementation
Death prior to hospital dis-
charge
Study populat ion RR 0.97
(0.80 to 1.17)
2877
(12 RCTs)
⊕⊕⊕⊕
HIGH
123 per 1000 119 per 1000
(98 to 144)
Moderate
80 per 1000 78 per 1000
(64 to 94)
Neurodevelopmental im-
pairment
Study populat ion RR 1.07
(0.59 to 1.92)
72
(1 RCT)
⊕⊕©©
LOW 1
375 per 1000 401 per 1000
(221 to 720)
Moderate
375 per 1000 401 per 1000
(221 to 720)
Invasive infect ion Study populat ion RR 0.94
(0.86 to 1.04)
2815
(11 RCTs)
⊕⊕⊕©
MODERATE 2,3
368 per 1000 346 per 1000
(316 to 383)
Moderate
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364 per 1000 342 per 1000
(313 to 379)
Necrot ising enterocolit is Study populat ion RR 0.83
(0.66 to 1.06)
2849
(11 RCTs)
⊕⊕⊕©
MODERATE 2,3
95 per 1000 79 per 1000
(63 to 101)
Moderate
72 per 1000 59 per 1000
(47 to 76)
¶ Enteral or parenteral route
1 Total sample size= 72
2 Unexplained heterogeneity
3 Funnel plot asymmetry
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B A C K G R O U N D
Glutamine is the most abundant amino acid in plasma and muscle
in humans (Bergström 1974).Under normal conditions glutamine
is the preferred respiratory fuel for rapidly proliferating cells such
as enterocytes and lymphocytes (Windmueller 1982; Newsholme
1985). It is a regulator of acid-base balance via ammonium, as
well as an important precursor of nucleic acids, nucleotides, amino
sugars and protein (Krebs 1980).
Description of the intervention
Endogenous biosynthesis of glutamine may be insufﬁcient for tis-
sue needs in states ofmetabolic stress. In these situations glutamine
appears to be “conditionally essential” (Lacey 1990). Glutamine
is abundant in human milk, but present only in much lower levels
in infant formula and not present in standard parenteral nutrition
solutions. It has been suggested that glutamine supplementation
may beneﬁt preterm infants.
How the intervention might work
In animal models of experimental enterocolitis, glutamine sup-
plementation has been associated with reduced mucosal damage,
improved nitrogen balance, lower rates of sepsis and higher levels
of survival (Klimberg 1990; Rombeau 1990). In studies in adult
humans, glutamine supplementation has been shown to attenuate
gut atrophy in the fasting state, maintain ATP levels in oxidant in-
jured cells, preserve immune cellularity of the gastrointestinal tract
during prolonged parenteral feeding and reduce post-operative de-
terioration in gastrointestinal permeability and mucosal integrity
(O’Dwyer 1989; Hinshaw 1990; Alverdy 1992; van der Hulst
1993). Parenteral glutamine in adults is well tolerated metaboli-
cally and appears to have no toxic effects (Ziegler 1990). The ﬁnd-
ings of systematic reviews of randomised controlled trials in adult
surgical or critically ill patients suggest that glutamine supplemen-
tation reduces infectious complications and duration of hospital
stay and may reduce mortality (Wischmeyer 2008; Avenell 2009).
Systematic reviews of randomised controlled trials found that pa-
tients undergoing bone marrow transplantation who receive par-
enteral nutrition with glutamine versus standard parenteral nu-
trition have fewer episodes of invasive infection (Crowther 2009;
Murray 2009). Larger trials of glutamine supplementation in these
populations are ongoing.
Why it is important to do this review
Given the ﬁndings in studies with adult participants, it is reason-
able to hypothesise that glutamine supplementation in preterm
infants (particularly very preterm infants) might enhance gastroin-
testinal mucosal integrity, thus improving enteral feed tolerance,
growth and development. Enhanced gastrointestinal barrier func-
tion and lymphocyte production might reduce the rate of late-
onset invasive infection or necrotising enterocolitis (NEC), and
so reduce mortality and adverse neurodevelopmental outcomes.
O B J E C T I V E S
Our objective was to determine the effects of glutamine sup-
plementation on mortality and morbidity in preterm infants.
We prespeciﬁed subgroup analyses of enteral and parenteral glu-
tamine supplementation because evidence from systematic reviews
of these interventions in adults suggests different effect sizes for
various outcomes (Avenell 2009).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included controlled trials using random or quasi-random par-
ticipant allocation. Due to the nature of the intervention, we ex-
cluded cross-over trials.
Where trials were reported as abstracts only, we aimed to include
them provided there was sufﬁcient information to assess eligibility.
We contacted the authors requesting further information if we
could not decide after reading the abstract.
Types of participants
We included preterm infants (gestational age < 37weeks) admitted
to neonatal intensive or special care units or comparable settings
after birth. Where participants in a trial included both term and
preterm infants, we sought subgroup data from the report or from
the authors.
Types of interventions
Glutamine supplementation versus no supplementation, admin-
istered by the parenteral or enteral route, in addition to a standard
nutrition regime.
Types of outcome measures
Studies were included in the review regardless of whether they
reported all outcome measures. If a study did not report these
outcomes we requested further information from the trial authors.
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Primary outcomes
1. Death prior to hospital discharge.
2. Neurodevelopment:
i) Neurodevelopmental outcomes assessed using
validated tools at ≥ 12 months post term.
ii) Classiﬁcations of disability, including non-ambulant
cerebral palsy, developmental delay and auditory and visual
impairment.
iii) Cognitive and educational outcomes at ≥ 5 years:
intelligence quotient and indices of educational achievement
measured using a validated tool (including school examination
results).
Secondary outcomes
1. Invasive infection during hospital admission as determined
by culture of bacteria or fungus from blood, cerebrospinal ﬂuid,
urine or from a normally sterile body space (number of
participants per group with one or more episodes).
2. NEC during hospital admission including at least two of
the following features:
i) Pneumatosis coli on abdominal radiograph.
ii) Abdominal distension/abdominal radiograph with
gaseous distension or frothy appearance of bowel lumen (or
both).
iii) Blood in stool.
iv) Lethargy, hypotonia or apnoea (or combination of
these).
3. Growth during the trial period: weight gain (g/day or g/kg/
day), linear growth (mm/week), head growth (mm/week),
skinfold thickness growth (mm/week).
4. Days from birth to establish full enteral tube feeds (at least
150 ml/kg/day), independently of parenteral ﬂuids or nutrition.
5. Days from birth to discharge to home from hospital.
Search methods for identification of studies
We used the standard search strategy of the Cochrane Neonatal
Review Group.
Electronic searches
We searched: the Cochrane Central Register of Controlled Tri-
als (CENTRAL), EMBASE (OvidSP), Maternity and Infant Care
(OvidSP), MEDLINE & MEDLINE in process (OvidSP) and
PubMed (until December 2015 updated from previous search in
November 2011) using the combination of text words and MeSH
terms described in Appendix 1.We did not apply language restric-
tions. Search ﬁlters were applied in EMBASE, MEDLINE and
PubMed to limit retrieval to clinical trials.
We searched Clinical Trials.gov, metaRegister of Controlled Trials
(mRCT), and the WHO International Clinical Trials Registry
Platform (ICTRP) for ongoing and completed trials.
Searching other resources
We examined the reference lists of studies identiﬁed as potentially
relevant. We also searched the abstracts from the annual meetings
of the Pediatric Academic Societies (1993 to 2015), the European
Society for Pediatric Research (1995 to 2014), the UK Royal Col-
lege of Paediatrics and Child Health (2000 to 2015) and the Peri-
natal Society of Australia and New Zealand (2000 to 2014). We
considered trials reported only as abstracts to be eligible if sufﬁ-
cient information was available, from the report or from contact
with the authors, to fulﬁl the inclusion criteria.
Data collection and analysis
We used the standard methods of the Cochrane Neonatal Review
Group.
Selection of studies
Two review authors screened the titles and abstracts of all studies
identiﬁed by the search.We assessed the full texts of any potentially
eligible reports and excluded those studies that did not meet all
of the inclusion criteria. We discussed any disagreements until
consensus was achieved.
Data extraction and management
We used a data collection form to aid extraction of relevant infor-
mation from each included study. One author extracted the data
and a second author checked the extracted data. Any disagree-
ments were discussed until consensus was achieved. We contacted
the investigators for further information if data from the trial re-
ports were insufﬁcient.
Assessment of risk of bias in included studies
We used the criteria and standard methods of the Cochrane
Neonatal Review Group to assess the methodological quality of
any included trials. Two authors conducted the assessment of risk
of bias. We resolved disagreements by discussion. We requested
additional information from the trial authors to clarify methodol-
ogy and results if necessary.
We made explicit judgements about whether studies were at high
risk of bias across four domains according to the criteria suggested
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011):
1. Random sequence generation - we categorised the method used
to generate the allocation sequence as having:
• low risk - any truly random process, e.g. random number
table, computer random number generator;
• high risk - any non-random process, e.g. odd or even date
of birth, hospital or clinic record number; or
• unclear risk - no or unclear information provided.
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2. Allocation concealment - we categorised the method used to
conceal the allocation sequence as having:
• low risk - e.g. telephone or central randomisation,
consecutively numbered sealed opaque envelopes;
• high risk - open random allocation, e.g. unsealed or non-
opaque envelopes, alternation, assignment determined by date of
birth; or
• unclear risk - no or unclear information provided.
3. Blinding - we assessed blinding of participants, clinicians and
caregivers, and outcome assessors separately for different outcomes
and categorised the methods as having:
• low risk;
• high risk; or
• unclear risk.
4. Incomplete outcome data - we described the completeness of
data, including attrition and exclusions from the analysis for each
outcome, and any reasons for attrition or exclusion, where re-
ported. We assessed whether missing data were balanced across
groups or were related to outcomes. Where sufﬁcient information
was reported or supplied by the trial authors, we planned to rein-
state missing data in the analyses. We categorised completeness as
having:
• low risk: ≤ 10% missing data;
• high risk: > 10% missing data; or
• unclear risk: no or unclear information provided.
Quality of evidence
We assessed the quality of evidence for the main comparisons at
the outcome level using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach (Guyatt
2011a). This methodological approach considers evidence from
randomised controlled trials as high quality that may be down-
graded based on consideration of any of ﬁve areas: design (risk of
bias), consistency across studies, directness of the evidence, preci-
sion of estimates and presence of publication bias. (Guyatt 2011a).
The GRADE approach results in an assessment of the quality of
a body of evidence in one of four grades: 1) High: We are very
conﬁdent that the true effect lies close to that of the estimate of
the effect; 2) Moderate: We are moderately conﬁdent in the effect
estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially differ-
ent; 3) Low: Our conﬁdence in the effect estimate is limited: The
true effect may be substantially different from the estimate of the
effect; 4) Very Low: We have very little conﬁdence in the effect
estimate: The true effect is likely to be substantially different from
the estimate of effect (Schünemann 2013).
Two review authors independently assessed the quality of the ev-
idence found for outcomes identiﬁed as critical or important for
clinical decision making: mortality and invasive infection.
In cases where we considered the risk of bias arising from inad-
equate concealment of allocation, randomised assignment, com-
plete follow-up or blinded outcome assessment to reduce our con-
ﬁdence in the effect estimates, we downgraded the quality of evi-
dence accordingly (Guyatt 2011b). Consistency was evaluated by
similarity of point estimates, extent of overlap of conﬁdence in-
tervals and statistical criteria including measurement of hetero-
geneity (I²). The quality of evidence was downgraded when in-
consistency across studies results was present being large and un-
explained (some studies suggest important beneﬁt and others no
effect or harm without a clinical explanation) (Guyatt 2011d).
Precision was assessed according with the 95% conﬁdence inter-
val around the pooled estimation (Guyatt 2011c). When trials
were conducted in populations other than the target population,
we downgraded the quality of evidence because of indirectness
(Guyatt 2011e).
The pooled estimates of the effects and 95% conﬁdence intervals
(CI) with explicit judgments for each of the above aspects assessed
were entered into the Guideline Development Tool, the software
used to create Summary of Findings (SoF) tables (GRADEpro
2008). All judgements involving the assessment of the study char-
acteristics described above were explained in foot notes or com-
ments in the SoF table.
Measures of treatment effect
We calculated relative risk (RR) and risk difference (RD) for di-
chotomous data and weighted mean difference (WMD) for con-
tinuous data, with respective 95% conﬁdence intervals (CI). We
determined the number needed to treat for beneﬁt (NNTB) or
harm (NNTH) for a statistically signiﬁcant difference in the RD.
Dealing with missing data
We requested outcome data from the trial investigators when these
were unavailable in the report. Speciﬁcally, we sought unpublished
data on the primary outcomes and on the incidence of NEC and
invasive infection for all trials. Further information on methodol-
ogy, especially with regard to the assessment of the risk of bias, was
also requested fromauthors if necessary. The tables ’Characteristics
of included studies’ report which information was obtained from
authors.
Assessment of heterogeneity
We examined the treatment effects of individual trials and hetero-
geneity between trial results by inspecting the forest plots if more
than one trial was included in a meta-analysis. We calculated the I²
statistic for each analysis to quantify inconsistency across studies
and describe the percentage of variability in effect estimates that
may be due to heterogeneity rather than sampling error. If sub-
stantial heterogeneity was detected (I² > 50%), we explored the
possible causes (for example, differences in study design, partici-
pants, interventions, or completeness of outcome assessments).
7Glutamine supplementation to prevent morbidity and mortality in preterm infants (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of reporting biases
We inspected a funnel plot for asymmetry if more than ten trials
were included in a meta-analysis.
Data synthesis
We used a ﬁxed-effect model for meta-analyses.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses:
1. Route of administration of glutamine supplementation:
enteral versus parenteral glutamine administration.
2. Trial setting (country): low- and middle-income versus
high-income countries (see: http://data.worldbank.org/about/
country-classiﬁcations)
R E S U L T S
Description of studies
See: Included studies; Excluded studies.
Results of the search
The updated search identiﬁed one new eligible trial (Pawlik 2012).
One publication of relevant follow-up data from van den Berg
2005 was identiﬁed and included in this review (de Kieviet 2012).
Several other publications of follow-up data were also identiﬁed
by the searches but were excluded as they did not report any of
our prespeciﬁed outcomes in addition to data already included in
this review.
The trial NCT00213668 was identiﬁed by our search of trial reg-
isters. Contact with the trial coordinator revealed that this trial
has been completed, however no publication of relevant outcomes
could be identiﬁed. NCT01263041 was also identiﬁed by our
searches as potentially relevant. We were unable to determine who
is responsible for this trial and hence do not know the current
status of this trial. These trials may be included in an update of
this review as results become available.
Included studies
We included 12 trials that fulﬁlled the eligibility criteria; nine
single-centre studies (Lacey 1996; Neu 1997; Thompson 2003;
Bober-Olesiñska 2005; van den Berg 2005; Korkmaz 2007;
Mohamad Ikram 2011; Sevastiadou 2011; Pawlik 2012), one trial
in two centres (Wang 2010) and two larger multi-centre trials
(Vaughn 2003; Poindexter 2004).
Participants
A total of 2877 preterm infants participated in the included trials;
2082 (72%) of these infants participated in the two largest trials
(Vaughn 2003; Poindexter 2004). All participating infants were
of very or extremely low birth weight and were recruited to a trial
within the ﬁrst few days of postnatal life.
Intervention
Six trials assessed the effect of parenteral glutamine supple-
mentation (Lacey 1996; Thompson 2003; Poindexter 2004;
Bober-Olesiñska 2005; Wang 2010; Mohamad Ikram 2011). The
other six trials examined the effect of enteral glutamine supplemen-
tation (Neu 1997; Vaughn 2003; van den Berg 2005; Korkmaz
2007; Sevastiadou 2011; Pawlik 2012).
Outcomes
Reported outcomes included mortality, the incidence of invasive
infection, NEC, the duration of parenteral nutrition administra-
tion, time taken to establish full enteral nutrition, rate of weight
gain and length of hospital admission. Poindexter 2004 and van
den Berg 2005 reported neurodevelopmental outcomes at 18 and
24 months post term, respectively. van den Berg 2005 reported
neurodevelopmental and cognitive outcomes at seven to eight
years of age.
Excluded studies
See: Characteristics of excluded studies.
Risk of bias in included studies
Allocation
Eight trials reported adequate allocation concealment methods
(randomisation in central pharmacy, computer generated sequence
in sealed opaque envelopes; Neu 1997; Thompson 2003; Vaughn
2003; Poindexter 2004; Bober-Olesiñska 2005; van den Berg
2005; Wang 2010; Mohamad Ikram 2011). Two trials were likely
to be “quasi-randomised” and did not report concealment of al-
location (Lacey 1996; Korkmaz 2007). Two trial reports did not
describe the randomisation and allocation procedure (Sevastiadou
2011; Pawlik 2012).
Blinding
All apart from two trial reports described the methods used for
blinding of caregivers and investigators (Korkmaz 2007; Pawlik
2012).
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Incomplete outcome data
Nine trials achieved complete or near-complete levels of follow-up
and reported intention-to-treat analyses (Neu 1997; Thompson
2003; Vaughn 2003; Poindexter 2004; Bober-Olesiñska 2005; van
denBerg 2005;Wang 2010; Sevastiadou 2011; Pawlik 2012). Two
trials did not report the drop out rate (Korkmaz 2007; Mohamad
Ikram 2011). Lacey 1996 reported post-recruitment withdrawal
of nearly 50% of participants, mainly due to non-compliance with
protocol.
Effects of interventions
See: Summary of findings for the main comparisonGlutamine
supplementation to prevent morbidity and mortality in preterm
infants
Glutamine supplementation versus no
supplementation (parenteral or enteral route)
Primary outcomes
Death prior to hospital discharge (Analysis 1.1)
None of the individual studies nor a meta-analyses of data from all
trials showed a statistically signiﬁcant difference (typical RR 0.97,
95% CI 0.80 to 1.17; typical RD 0.00, 95% CI -0.03 to 0.02;
12 studies, 2877 infants; Analysis 1.1). There was no evidence of
statistical heterogeneity or funnel plot asymmetry (Figure 1).
Figure 1. Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome:
1.1 Death prior to hospital discharge.
Neurodevelopment (Analysis 1.2)
Poindexter 2004 conducted follow-up assessments of about 89%
of the surviving infants at 18 to 22 months post term. This in-
cluded neurological examination and developmental assessment
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using Bayley Scales of Infant Development II (BSID-II) Mental,
Motor and Behavior Rating Scales. The investigators reported that
they did not ﬁnd any statistically signiﬁcant differences between
the groups for any of the outcomes assessed but numerical data
are not published or yet available. Thirty month follow-up on all
of these infants was also planned. We could not ﬁnd these data for
inclusion in this review. They will be included in a future update
if they become available.
van den Berg 2005 reported neurodevelopmental outcomes for
infants aged two years post term. Outcomes assessed included the
mental development index (MDI) and psychomotor development
index (PDI) subscales of the BSID-II, incidence of cerebral palsy
and visual and hearing impairment. No signiﬁcant differences be-
tween the glutamine and the control groups were reported for any
of these individual outcomes or for a composite of neurodevelop-
mental impairment consisting of any of the following: MDI≤ 85,
PDI≤ 85, cerebral palsy, blindness in one or both eyes or hearing
loss requiring ampliﬁcation (RR 1.07, 95% CI 0.59 to 1.92; RD
0.03, 95% CI -0.20 to 0.25; 1 study, 72 infants; Analysis 1.2).
van den Berg 2005 reported follow-up assessments of 68 children
aged 7 to 8 years. Four of these children had serious motor (n =
2), hearing (n = 1), or visual (n = 1) difﬁculties which prevented
them from participating; it is not known if these children received
glutamine or placebo. Of the remaining 64 children, 30 had re-
ceived glutamine after birth and 34 had received placebo. The trial
did not show any signiﬁcant differences in intelligence quotient,
processing speed, attention level, working memory and parent-
and teacher-rated behavioural outcomes.
Secondary outcomes
Invasive infection (Analysis 1.3)
Data were available from eleven trials (Lacey 1996; Neu
1997; Thompson 2003; Vaughn 2003; Poindexter 2004; Bober-
Olesiñska 2005; van den Berg 2005; Korkmaz 2007; Mohamad
Ikram 2011; Sevastiadou 2011; Pawlik 2012). Two trials found
a statistically signiﬁcant lower incidence in infants who received
glutamine (van den Berg 2005; Sevastiadou 2011), but none of the
other trials nor a meta-analysis of all of the data found a statisti-
cally signiﬁcant difference (typical RR 0.94, 95%CI 0.86 to 1.04;
typical RD -0.02, 95% CI -0.06 to 0.01; 11 studies, 2815 infants;
Analysis 1.3). There was evidence of statistical heterogeneity (I² =
58%) and funnel plot asymmetry (Figure 2).
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Figure 2. Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome:
1.3 Invasive infection.
Necrotising enterocolitis (Analysis 1.4)
None of the eleven individual studies that reported this out-
come found a statistically signiﬁcant difference (Lacey 1996;
Neu 1997; Thompson 2003; Vaughn 2003; Poindexter 2004;
Bober-Olesiñska 2005; van den Berg 2005; Korkmaz 2007;
Mohamad Ikram 2011; Sevastiadou 2011; Pawlik 2012). Meta-
analysis did not reveal a statistically signiﬁcant difference (typical
RR 0.83, 95% CI 0.66 to 1.06; typical RD -0.02, 95% CI -0.04
to 0.00; 11 studies, 2879 infants; Analysis 1.4). There was some
evidence of statistical heterogeneity (I² = 31%), as well as funnel
plot asymmetry (Figure 3).
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Figure 3. Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome:
1.4 Necrotising enterocolitis.
Growth during the trial period (Analysis 1.5)
Meta-analysis of data from three trials did not reveal a statistically
signiﬁcant difference in the rate ofweight gain in grams/day during
the study period (WMD0.59, 95%CI -1.42 to 2.59; Analysis 1.5)
Therewas evidence of statistical heterogeneity (I² = 40%) (Analysis
1.5). Four trials reported no statistically signiﬁcant differences in
the rate of weight gain or meanweight at the end of the trial period
but did not provide data that could be included in meta-analyses
(Neu 1997; Vaughn 2003; Poindexter 2004; van den Berg 2005).
Korkmaz 2007 reported that the rate of gain in weight and length
and head circumference was higher in the glutamine group than
controls up to the end of the 120 day intervention period, but
numerical data (including number of participants assessed at each
monthly interval) were not available for inclusion in the meta-
analysis.
Days from birth to establish full enteral feeds (Analysis 1.6)
Data were available from seven studies (Lacey 1996; Thompson
2003; Poindexter 2004; van den Berg 2005; Korkmaz 2007;Wang
2010; Mohamad Ikram 2011). Thompson 2003 reported a statis-
tically signiﬁcant shorter time to full enteral nutrition in the glu-
tamine group while the other studies did not ﬁnd any signiﬁcant
differences. Meta-analysis of data from all of these trials showed a
statistically signiﬁcant difference between glutamine and control
groups in days to full enteral feeds (WMD -1.68, 95% CI -2.88
to -0.48; Analysis 1.6). Statistical heterogeneity was not evident
(I² = 13%), nor was funnel plot asymmetry (Figure 4).
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Figure 4. Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome:
1.6 Time to full enteral nutrition (days).
Days from birth to discharge to home from hospital
(Analysis 1.7)
Data were available from eight trials (Lacey 1996; Thompson
2003; Vaughn 2003; Poindexter 2004; van den Berg 2005;
Korkmaz 2007;Wang 2010;Mohamad Ikram 2011). None of the
trials nor a meta-analysis of all data found a statistically signiﬁcant
difference between the glutamine and the control group in days
from birth to discharge to home in days (WMD -0.85, 95% CI -
3.39 to 1.70; Analysis 1.7). Statistical heterogeneity was not evi-
dent (I² = 0%), nor was funnel plot asymmetry (Figure 5).
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Figure 5. Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome:
1.7 Duration of hospital stay (days).
Subgroup analyses
Enteral glutamine supplementation
Six trials examined the effect of enteral glutamine supplementation
(Neu 1997; Vaughn 2003; van den Berg 2005; Korkmaz 2007;
Sevastiadou 2011; Pawlik 2012). Meta-analysis of the available
data did not show statistically signiﬁcant effects on mortality or
NEC (Analysis 1.1; Analysis 1.4).
Meta-analysis showed a statistically signiﬁcant lower incidence of
invasive infection in the enteral glutamine supplemented group
(typical RR 0.76, 95% CI 0.64 to 0.89; typical RD -0.09, 95%CI
-0.14 to -0.04;NNTB11, 05%CI 7 to 25; 6 studies, 1095 infants)
(Analysis 1.3). The meta-analysis contained substantial statistical
heterogeneity (I² = 56%) which remained in a sensitivity analysis
in which the quasi-randomised trial was omitted (Korkmaz 2007).
Meta-analysis of data from two trials (van denBerg 2005;Korkmaz
2007) showed a statistically signiﬁcant difference in time to reach
full enteral feeds (WMD -2.63 days, 95% CI -4.99 to -0.27)
(Analysis 1.6).Meta-analysis of three trials (Vaughn 2003; van den
Berg 2005; Korkmaz 2007) did not ﬁnd a statistically signiﬁcant
difference in duration of hospital stay (Analysis 1.7).
Parenteral glutamine supplementation
Six trials examined the effect of parenteral glutamine supple-
mentation (Lacey 1996; Thompson 2003; Poindexter 2004;
Bober-Olesiñska 2005; Wang 2010; Mohamad Ikram 2011).
Meta-analyses did not detect any statistically signiﬁcant effects on
mortality, incidence of invasive infection, incidence of NEC, rate
of weight gain, time to full enteral nutrition, or duration of hos-
pital stay (Analysis 1.1; Analysis 1.3; Analysis 1.5; Analysis 1.6;
Analysis 1.7). Substantial heterogeneity was not evident in any of
these meta-analyses.
Low- or middle-income countries (Analyses 2.1-2.6)
Three of the trials were undertaken in middle-income countries:
Turkey (Korkmaz 2007), Malaysia (Mohamad Ikram 2011), and
China (Wang 2010). Meta-analyses did not detect any statistically
signiﬁcant effects onmortality (Analysis 2.1), incidence of invasive
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infection (Analysis 2.2), NEC (Analysis 2.3), rate of weight gain
(Analysis 2.4), time to full enteral feeds (Analysis 2.5), or duration
of hospital stay (Analysis 2.6). Statistical heterogeneity was not
evident in any of these meta-analyses.
D I S C U S S I O N
Summary of main results
The major ﬁnding of this review of 12 randomised controlled tri-
als is that glutamine supplementation does not have a statistically
signiﬁcant effect onmortality in preterm infants. The narrow 95%
CI around the estimate of effect suggests that a modest but clin-
ically important difference has not been missed. Data from three
of the trials also indicate that glutamine supplementation does not
have an important effect on neurodevelopmental outcomes. With
regard to secondary outcomes, we did not ﬁnd evidence of an ef-
fect on major neonatal morbidities including the rate of invasive
infection and the incidence of NEC.
In a pre-speciﬁed subgroup analysis, we found that enteral (but
not parenteral) glutamine supplementation resulted in a statisti-
cally signiﬁcant reduction in the incidence of invasive infection.
However, the meta-analysis contained substantial heterogeneity
not explained by variation in study design and methodological
quality (randomised versus quasi-randomised). In a meta-analysis
of two trials, enteral glutamine supplementation resulted in a 2.6
days reduction in the time taken to achieve full enteral nutrition.
Given the potential clinical importance of these ﬁndings, further
evaluation of enteral glutamine supplementation may be merited
as advocated by van Zwol 2011. Currently, two trials of enteral
glutamine supplementation in preterm infants are ongoing and
their ﬁndings may be incorporated into an update of this review
(NCT00213668; NCT01263041).
Quality of the evidence
The interpretation of the review ﬁndings is limited by the exis-
tence of methodological weaknesses associated with the potential
for bias in some of the trials (Figure 6). Themain concern is lack of
evidence of methods to preserve allocation concealment in four of
the trials (Lacey 1996; Korkmaz 2007; Sevastiadou 2011; Pawlik
2012). However, in general the trials were of good quality and
analyses with quasi-randomised trials omitted did not alter statis-
tical heterogeneity or the overall size of the treatment effects.
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Figure 6. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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The other methodological limitation present in one of the trials
was incomplete outcome assessment (Lacey 1996). This trial re-
ported post-recruitment withdrawal of nearly 50%of participants,
mainly due to non-compliance with protocol issues. Intention-to-
treat re-analysis was not possible. Removal of this trial in sensi-
tivity analyses did not affect the level of heterogeneity or size of
treatment effect.
Potential biases in the review process
The main concern with the review process is the possibility that
the ﬁndings are subject to publication and other reporting biases;
in other words, that there may be a greater availability of data
for inclusion in meta-analyses from trials which reported statisti-
cally signiﬁcant or clinically important effects (Hopewell 2007a;
Hopewell 2007b; Hopewell 2009). We attempted to minimise
this threat by searching the proceedings of the major international
perinatal conferences to identify trial reports that were not pub-
lished in full form in academic journals (Young 2011). However,
we cannot be sure that other trials have not been undertaken but
not reported, and the concern remains that such trials are less
likely than published trials to have detected statistically signiﬁcant
or clinically important effects. Some of the meta-analyses that we
performed demonstrated funnel plot asymmetry consistent with
possible publication or reporting bias (Figure 2).
Agreements and disagreements with other
studies or reviews
The biologically plausible effects of glutamine supplementation
relate to its role in the repair and growth of rapidly dividing cells.
This action is consistent with the evidence of beneﬁt of glutamine
supplementation in critically ill adult patients (Wischmeyer 2008;
Avenell 2009). Although the population of preterm infants who
participated in the trials identiﬁed in this review were all of very
low birth weight (and of extremely low birth weight in the largest
trial), it may be that any beneﬁts of glutamine supplementation
are conﬁned to those infants who are critically ill, for example with
severe gastrointestinal disease such as NEC. Glutamine supple-
mentation may be beneﬁcial in the recovery phase of these illnesses
when infants are severely metabolically compromised and glu-
tamine availability is rate-limiting for tissue repair (Brown 2014).
Additionally, many of the participating infants in the included tri-
als may not have been truly glutamine-deﬁcient as they received
glutamine from breast milk, or received glutamate (a precursor for
glutamine) from milk, formula, or parenteral nutrition.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available data from randomised controlled trials suggests that
the routine use of glutamine supplementation does not have an
important effect on mortality or neonatal morbidity in preterm
infants. Some limited evidence exists that enteral glutamine sup-
plementation reduces the time to reach full enteral nutrition and
the rate of late-onset invasive infection in preterm infants; this
ﬁnding should be interpreted with caution because of the poten-
tial for bias in the included trials.
Implications for research
Follow-up of infants who participated in the trials identiﬁed in
this review might provide further data on the effect of this in-
tervention on growth through later childhood, speciﬁcally later
neurodevelopmental outcomes. Further evaluation of routine par-
enteral glutamine supplementation in preterm infants is unlikely
to be considered a research priority, but this review does provide
some support for further trials of enteral glutamine supplemen-
tation to be undertaken (van Zwol 2011). It may also be appro-
priate to focus research effort on assessing the effect of glutamine
supplementation as a treatment for preterm infants with severe
gastrointestinal disease (Brown 2014).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bober-Olesiñska 2005
Methods Randomised controlled trial
Participants 55 very low birth weight infants
Interventions Treatment: glutamine dipeptide added to standard parenteral nutrition solution to make
20% of total amino acid content (n = 25)
Control: no added glutamine (n = 30)
Outcomes Invasive infection and rate of NEC
Notes Abstract in English. Article in Polish. Further information received courtesy of Dr Bober-
Olesiñska
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention and outcome measurement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow up assessment
Korkmaz 2007
Methods Quasi-randomised controlled trial
Participants 69 very low birth weight infants (appropriate birth weight for gestational age)
Exclusion criteria: congenital malformations, chromosomal abnormalities, inherited
metabolic diseases, receipt of enteral feeding for < 1 week or mechanical ventilation for >
4 weeks, those developing post-haemorrhagic hydrocephalus after grade III to IV intra-
ventricular haemorrhage
Interventions Treatment: enteral glutamine supplementation (300 mg/kg/day) between 8-120 days
after birth (n = 36)
Control: sterile water (n = 33)
22Glutamine supplementation to prevent morbidity and mortality in preterm infants (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Korkmaz 2007 (Continued)
Outcomes Growth parameters (weight, length, head circumference, left upper mid-arm circumfer-
ence, left mid-thigh circumference during trial period (4 months))
Incidence of invasive infection
Time to full enteral nutrition
Duration of hospital stay
Notes Data on mortality and NEC incidence supplied by trial investigators
Setting: Neonatal Intensive Care Unit and neonatal follow-up clinic of Hacettepe Uni-
versity, Ihsan Dogramaci Children’s Hospital, Anakara, Turkey (early 2000s)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised allocation of participants ac-
cording to the order of admission
Allocation concealment (selection bias) High risk Quasi-randomised allocation of participants ac-
cording to the order of admission
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported, number presumed to be followed up:
36 and 33
Lacey 1996
Methods Randomised controlled trial
Participants 78 infants aged < 4 days, receiving parenteral nutrition for < 3 days
Must have met > 5 of the following criteria: birth weight < 1500 g, gestational age < 32
weeks, 5-minute Apgar score < 6, need for > 21% oxygen, need for ventilatory assistance,
low blood pressure for age, suspected intraventricular haemorrhage, presence of patent
ductus arteriosus, presence of umbilical, arterial and venous catheters and birth weight
< 1000 g
Interventions Treatment: glutamine added to parenteral nutrition solution (n = 38)
Control: parenteral nutrition without added glutamine (n = 39)
Outcomes Time to full enteral feeds, duration of administration of parenteral nutrition, duration
of mechanical ventilation, average weight gain per day, duration of hospital stay
Notes Glutamine was added to parenteral nutrition at concentrations of between 15% and
25% weight per volume of the amino acid mix. The protocol speciﬁed that participating
infants should continue to receive parenteral nutrition for at least seven days
23Glutamine supplementation to prevent morbidity and mortality in preterm infants (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lacey 1996 (Continued)
Setting: Brigham and Women’s Hospital, Boston, USA (early 1990s)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) High risk First four infants allocated to intervention group and sub-
sequent participants allocated by “balanced assignment”
- unclear if this was concealed, may be quasi-randomisa-
tion
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators, nursing staff and dieticians blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the 78 infants originally enrolled, 34 were subse-
quently excluded for the following reasons: insufﬁcient
time on parenteral nutrition (8 treated and 8 control),
surgery or transfer (1 treated and 3 control), development
of NEC (2 treatment and 2 control) or death (5 treat-
ment and 4 control). One was excluded as a “statistical
outlier” (allocation not stated). We have not been able
to re-analyse the outcomes for all of the enrolled infants
(intention-to-treat)
Mohamad Ikram 2011
Methods Randomised controlled trial
Participants 154 newborn infants aged < 72 hours and receiving parenteral nutrition
Exclusion criteria: chromosomal abnormalities or inborn metabolism errors, those born
from consanguineous marriage and those anticipated to require < 48 hours parenteral
nutrition
Interventions Treatment: 20% glutamine solution added to standard parenteral nutrition (n = 76)
Control: standard parenteral nutrition (n = 78)
Outcomes Mortality, invasive infection, NEC, time to full enteral nutrition, time to discharge
Notes Trial included term and preterm infants, subgroup data for preterm infants were provided
by authors
Setting: Neonatal Intensive Care Unit at Hospital Universiti Sains, Malaysia
Risk of bias
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Mohamad Ikram 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly permuted blocks
Allocation concealment (selection bias) Low risk Randomisation sequence was generated by a person who
was not directly involved in recruitment or care of the
infants
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators and treating staff blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow up assessment
Neu 1997
Methods Randomised controlled trial
Participants 68 newborn infants (birth weight 500 - 1250 grams, gestational age 24 - 32 weeks) aged
< 3 days
Exclusion criteria: congenital anomalies of gastrointestinal tract, NEC, major surgery,
breast fed infants, infants considered nonviable
Duration: 3 - 30 days of life
Interventions Treatment: enteral glutamine added to commercial preterm formula feed (n = 35)
Control: no added glutamine (n = 33)
Outcomes Mortality, invasive infection, NEC, duration of hospital stay
Notes The intervention group received 0.08 g/kg/day of glutamine at the start of the study
(day 3), increasing to 0.31 g/kg/day by day 13. Glutamine supplementation was stopped
on day 30. All infants received the same level of parenteral nutrition (without added
glutamine) while enteral feeds were being advanced
Setting: Neonatal Intensive Care Unit, Shands Hospital at University of Florida, USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Low risk Sealed envelopes
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Neu 1997 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk All investigators and caregivers blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 68 infants enrolled, 27 were withdrawn from the
study for the following reasons: transfer (1 treated and
1 control), illness or intolerance of enteral feeding (9
treated and 16 control). All but the two infants who were
transferred from the study centre were included in the
analysis whether they were able to adhere completely to
the feeding protocol or not
Pawlik 2012
Methods Randomised controlled trial
Participants 106 very low birth weight infants
Interventions Treatment: glutamine/amino acid solution added to usual human milk or formula (n =
50)
Control: human milk or formula without added glutamine (n = 56)
Outcomes Feeding intolerance, NEC, intestinal perforation, sepsis, mortality
Notes Paper published in Polish with only the abstract and some outcome data available in
English. Despite contacting the authors, no further details could be obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methological details were not reported in the abstract.
This table will be updated if further details are made
available to us by the authors
Allocation concealment (selection bias) Unclear risk Methological details were not reported in the abstract.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Methological details were not reported in the abstract.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Methological details were not reported in the abstract.
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Poindexter 2004
Methods Randomised controlled trial
Participants 1433 extremely low birth weight infants enrolled within 72 hours of birth
Exclusion criteria: major congenital anomalies, congenital non-bacterial infection, ter-
minal illness, decision made not to provide full intensive care and support
Duration: birth to 120 days
Interventions Treatment: 20% glutamine added to standard parenteral nutrition solution (n = 721)
Control: no added glutamine (n = 712)
Outcomes Primary: Composite outcome of death or late-onset sepsis
Secondary: Number of episodes of late-onset invasive infection, rate of NEC, duration
of mechanical ventilation, length of hospital stay, measures of feeding tolerance and
intolerance, duration of parenteral nutrition, growth parameters
Notes Setting: 15 neonatal care centres in the USA (1999-2001)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generated by data coordination centre
Allocation concealment (selection bias) Low risk Hospital pharmacists allocated infants to control or glu-
tamine group
Blinding (performance bias and detection
bias)
All outcomes
Low risk The caregivers were not aware whether participating in-
fants received glutamine-supplemented or non-supple-
mented parenteral nutrition
Incomplete outcome data (attrition bias)
All outcomes
Low risk One baby (glutamine) lost to follow-up
Sevastiadou 2011
Methods Randomised controlled trial
Participants 101 formula fed preterm infants, birth weight < 2 kg, gestational age < 34 weeks
Exclusion criteria: congenital or chromosomal anomalies, severe hypotension, severe
perinatal distress, abdominal distention, signs of early NEC
Duration: 3 - 30 days
Interventions Treatment: 10% glutamine solution, administered enterally 3x daily (n = 51), dosage
adjusted to actual weight (0.3 g/kg/day)
Control: isocaloric “caloreen” (glucose polymer) supplementation (n = 50)
Outcomes Measures of intestinal permeability
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Sevastiadou 2011 (Continued)
Notes Unpublished invasive infection and NEC data provided by authors
Setting: Neonatal Intensive Care Unit at Alexandra Regional General Hospital, Greece
(2007-8)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Nursing staff blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 25 participants exited the study after randomisation (16
in control group: 4 died, in 12 urine collection failed; 9
in glutamine group: 3 died, in 6 urine collection failed)
Thompson 2003
Methods Randomised controlled trial
Participants 35 very low birth weight infants with a need for mechanical ventilation or more than
40% oxygen enrolled on day one of postnatal life
Exclusion criteria: renal or hepatic dysfunction, suspected congenital anomalies of the
gastrointestinal tract, lethal congenital anomalies
Interventions Treatment: 2.5% glutamine solution given along with standard parenteral nutrition (n
= 17), increased to maximum of 3 g/kg/day
Control: sterile water with no added glutamine (n = 18)
Outcomes Time to full enteral feeds, number of episodes of sepsis, rate of weight gain, measures of
feeding tolerance and intolerance, rate of NEC
Notes Infants in the intervention group received a solution of 2.5% L-glutamine given as
a separate but simultaneous infusion with the remainder of the parenteral nutrition.
The glutamine comprised approximately 16% of total amino acids. Control infants
received an infusion of water indistinguishable in appearance to the glutamine solution.
Parenteral nutrition and glutamine supplementation was discontinued when enteral
feeding exceeded 80% of total energy requirements
Setting: Regional Neonatal Unit in Royal Maternity Hospital, Belfast, UK (late 1990s)
Risk of bias
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Thompson 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Four-block randomisation sequence generated off-site
Allocation concealment (selection bias) Low risk Hospital pharmacists randomly allocated one solution to
be control and one to be glutamine supplemented
Blinding (performance bias and detection
bias)
All outcomes
Low risk Main researcher, medical and nursing staff blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 infants in the glutamine group and 2 in the control
group died
van den Berg 2005
Methods Randomised controlled trial
Participants 107 very low birth weight or very preterm infants
Exclusion criteria: major congenital or chromosomal anomalies, death or transfer to
another hospital within 48 hrs of birth, admission from extra regional hospital
Duration: 3 - 30 days of life
Interventions Treatment: enteral glutamine supplementation to breast milk or formula (up to 0.3 g/
kg/day; n = 54), after two weeks the dosage was adjusted to actual weight of the infants
Control: placebo (alanine) in breast milk or formula (n = 53)
Outcomes Primary: time to full enteral feeding
Secondary: other variables of feeding tolerance, NEC, days of no enteral feeding, in-
cidence of serious infection, growth, need for mechanical ventilation, age at discharge,
death
Neurodevelopmental outcomes
Cognitive development, cerebral palsy, blindness and hearing loss were assessed at 24
months corrected age. Out of the 107 infants initially randomised, 88 were eligible for
2 year follow-up. Data were available for 72 infants (glutamine: n = 40, control: n = 32)
On follow-up at age 7 to 8 years, 68 children were assessed. Four of these children had
serious motor (n = 2), hearing (n = 1), or visual (n = 1) difﬁculties which hindered
them from participation. It is not known if these children received glutamine or placebo.
Parents and teachers completed questionnaires addressing any behavioural problems at
home or in school, respectively. The following cognitive and motor measures were also
assessed: theWechsler Intelligence Scale for Children to assess intellectual development,
the Movement Assessment Battery for Children to assess motor development, and an
adapted version of the Attention Network Test to assess orienting, executive, and alerting
attention
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van den Berg 2005 (Continued)
Notes After randomisation 5 infants were excluded due to clinical complications, therefore
glutamine group n = 52, control n = 50
Setting: Level III Neonatal Intensive Care Unit of VU University Medical Centre, Am-
sterdam, The Netherlands
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation table based on
blocks of four
Allocation concealment (selection bias) Low risk Sealed code batch numbers
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators, parents, medical and nursing staff were not
aware which solution infants received
Incomplete outcome data (attrition bias)
All outcomes
High risk 17 (glutamine) and 11 (control) infants were lost to fol-
low-up
Vaughn 2003
Methods Randomised controlled trial
Participants 649 newborn infants with birth weight 500 - 1250 grams
Exclusion criteria:major chromosomal or congenital anomalies, high probability of death
within 3 days, diagnosed with NEC within 7 days after birth
Duration: between 7 days and 36 weeks
Interventions Treatment: 5 ml/kg of 3% glutamine solution given enterally 12-hourly for the ﬁrst 28
days (n = 314); dosage not adjusted to weight
Control: sterile water with no added glutamine (n = 335)
Outcomes Primary: Number of infants with positive blood cultures from 7 days to 36 weeks post-
menstrual age
Secondary: Number of episodes of sepsis, measures of growth, rates of other neonatal
morbidities including NEC, and length of hospital stay
Notes Glutamine/control solution given at the same time but separate from milk feeds
Setting: 20 neonatal care centres in the USA (late 1990s)
Risk of bias
Bias Authors’ judgement Support for judgement
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Vaughn 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Blocks of 10 for each of 3 birth weight strata
Allocation concealment (selection bias) Low risk Sequentially numbered opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Caregiverswere not awarewhich solution infants received
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although 105 (56 treated and 49 control) infants left the
study before completing a full course of treatment due to
death (39), transfer to another hospital (24), NEC (24),
meeting exclusion criteria after enrolment (12), discharge
home (2) and parental request (4), outcome analyses in
the published report and in this review are intention-to-
treat
Wang 2010
Methods Randomised controlled trial
Participants 28 very low birth weight infants receiving parenteral nutrition for at least 7 days
Exclusion criteria: pre-existing renal or hepatic dysfunction, congenital errors of
metabolism, major chromosomal disease, cytomegalovirus infection, viral hepatitis, con-
genital or acquired immune deﬁciency
Interventions Intervention: parenteral glutamine 0.3 g/kg/day added to parenteral nutrition
Control: no glutamine (6% amino acid)
Outcomes Time to full enteral nutrition, weight gain, head circumference, length of hospitalisation,
days on ventilator
Notes Data on invasive infection, NEC, time to full enteral nutrition, and duration of hospital
stay were requested from the authors (not available May 2014)
Setting: two neonatal care centres in China (mid-late 2000s)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Unique randomisation code
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators, parents, physicians, nurses blinded
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Wang 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk n = 4 from control group and n = 2 from glutamine group
were withdrawn
NEC = necrotising enterocolitis
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barbosa 1999 No preterm infants
Li 2007 Not a randomised controlled trial
Strujis 2013 Term infants, average gestational age 37 weeks
Characteristics of ongoing studies [ordered by study ID]
NCT00213668
Trial name or title Effect of Glutamine on Gastric Emptying and Length of Parenteral Nutrition in Premature Neonates
Methods Randomised controlled trial
Participants Premature neonates
Interventions Dietary supplement: glutamine (dipeptiven)
Outcomes Primary outcome measure: gastric emptying
Secondary outcome measures: intestinal transit time, age at total enteral nutrition, age at the end of hospital-
isation, variation of cholecystokinin and gastrin postprandial concentration
Starting date April 2002
Contact information Contact: Anne Mercier, MD
02-32-88-80-97 ext 02-33-89-42-62
anne.mercier@ch-avranches-granville.fr
Notes
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NCT01263041
Trial name or title Effect of L-arginine and Glutamine on Preterm (preterm)
Methods Randomised controlled trial
Participants Preterm infants
Interventions Drug: enteral glutamine
Drug: l-arginine
Other: placebo
Outcomes Primary outcome measures: necrotising enterocolitis incidence, sepsis incidence, severity and outcome
Secondary outcome measures: incidence, severity and outcome of respiratory distress syndrome, pulmonary
hypertension, intracranial haemorrhage
Starting date December 2010
Contact information Prof. Hesham Awad
Ain Shams University
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Glutamine supplementation versus no supplementation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death prior to hospital discharge 12 2877 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.80, 1.17]
1.1 Enteral supplementation 6 1095 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.58, 1.49]
1.2 Parenteral
supplementation
6 1782 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.79, 1.20]
2 Neurodevelopmental
impairment
1 72 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.59, 1.92]
2.1 Enteral supplementation 1 72 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.59, 1.92]
2.2 Parenteral
supplementation
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Invasive infection 11 2815 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.86, 1.04]
3.1 Enteral supplementation 6 1095 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.64, 0.89]
3.2 Parenteral
supplementation
5 1720 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.94, 1.20]
4 Necrotising enterocolitis 11 2849 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.06]
4.1 Enteral supplementation 7 1172 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.49, 1.08]
4.2 Parenteral
supplementation
4 1677 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.67, 1.22]
5 Rate of weight gain (g/day) 3 100 Mean Difference (IV, Fixed, 95% CI) 0.59 [-1.42, 2.59]
5.1 Enteral supplementation 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Parenteral
supplementation
3 100 Mean Difference (IV, Fixed, 95% CI) 0.59 [-1.42, 2.59]
6 Time to full enteral nutrition
(days)
7 1594 Mean Difference (IV, Fixed, 95% CI) -1.68 [-2.88, -0.48]
6.1 Enteral supplementation 2 171 Mean Difference (IV, Fixed, 95% CI) -2.63 [-4.99, -0.27]
6.2 Parenteral
supplementation
5 1423 Mean Difference (IV, Fixed, 95% CI) -1.35 [-2.74, 0.05]
7 Duration of hospital stay (days) 8 2174 Mean Difference (IV, Random, 95% CI) -0.85 [-3.39, 1.70]
7.1 Enteral supplementation 3 753 Mean Difference (IV, Random, 95% CI) -1.32 [-5.55, 2.92]
7.2 Parenteral
supplementation
5 1421 Mean Difference (IV, Random, 95% CI) -0.58 [-3.77, 2.61]
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Comparison 2. Trials in low- and middle-income countries
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death prior to hospital discharge 3 251 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.35, 1.90]
2 Invasive infection 2 223 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.45, 1.36]
3 Necrotising enterocolitis 2 223 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.21, 1.43]
4 Rate of weight gain (g/day) 1 28 Mean Difference (IV, Fixed, 95% CI) -2.60 [-7.57, 2.37]
5 Time to full enteral nutrition
(days)
3 251 Mean Difference (IV, Fixed, 95% CI) -1.44 [-3.20, 0.33]
6 Duration of hospital stay (days) 3 236 Mean Difference (IV, Fixed, 95% CI) -1.85 [-5.77, 2.07]
Analysis 1.1. Comparison 1 Glutamine supplementation versus no supplementation, Outcome 1 Death
prior to hospital discharge.
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 1 Glutamine supplementation versus no supplementation
Outcome: 1 Death prior to hospital discharge
Study or subgroup Glutamine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Enteral supplementation
Neu 1997 1/35 3/33 1.7 % 0.31 [ 0.03, 2.87 ]
Vaughn 2003 15/314 18/335 9.8 % 0.89 [ 0.46, 1.73 ]
van den Berg 2005 8/52 4/50 2.3 % 1.92 [ 0.62, 5.99 ]
Korkmaz 2007 3/36 2/33 1.2 % 1.38 [ 0.24, 7.72 ]
Sevastiadou 2011 3/51 4/50 2.3 % 0.74 [ 0.17, 3.12 ]
Pawlik 2012 1/50 3/56 1.6 % 0.37 [ 0.04, 3.47 ]
Subtotal (95% CI) 538 557 18.9 % 0.93 [ 0.58, 1.49 ]
Total events: 31 (Glutamine), 34 (Control)
Heterogeneity: Chi2 = 3.45, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
2 Parenteral supplementation
Lacey 1996 5/38 4/39 2.2 % 1.28 [ 0.37, 4.42 ]
Thompson 2003 5/17 2/18 1.1 % 2.65 [ 0.59, 11.86 ]
Poindexter 2004 124/721 127/712 71.8 % 0.96 [ 0.77, 1.21 ]
Bober-Olesi ska 2005 1/25 2/30 1.0 % 0.60 [ 0.06, 6.24 ]
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(. . . Continued)
Study or subgroup Glutamine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wang 2010 0/13 0/15 Not estimable
Mohamad Ikram 2011 6/76 9/78 5.0 % 0.68 [ 0.26, 1.83 ]
Subtotal (95% CI) 890 892 81.1 % 0.97 [ 0.79, 1.20 ]
Total events: 141 (Glutamine), 144 (Control)
Heterogeneity: Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
Total (95% CI) 1428 1449 100.0 % 0.97 [ 0.80, 1.17 ]
Total events: 172 (Glutamine), 178 (Control)
Heterogeneity: Chi2 = 6.03, df = 10 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 1.2. Comparison 1 Glutamine supplementation versus no supplementation, Outcome 2
Neurodevelopmental impairment.
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 1 Glutamine supplementation versus no supplementation
Outcome: 2 Neurodevelopmental impairment
Study or subgroup Glutamine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Enteral supplementation
van den Berg 2005 16/40 12/32 100.0 % 1.07 [ 0.59, 1.92 ]
Subtotal (95% CI) 40 32 100.0 % 1.07 [ 0.59, 1.92 ]
Total events: 16 (Glutamine), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
2 Parenteral supplementation
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Glutamine), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 40 32 100.0 % 1.07 [ 0.59, 1.92 ]
Total events: 16 (Glutamine), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Glutamine supplementation versus no supplementation, Outcome 3 Invasive
infection.
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 1 Glutamine supplementation versus no supplementation
Outcome: 3 Invasive infection
Study or subgroup Glutamine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Enteral supplementation
Neu 1997 4/35 10/33 2.0 % 0.38 [ 0.13, 1.09 ]
Vaughn 2003 106/314 122/335 22.8 % 0.93 [ 0.75, 1.14 ]
van den Berg 2005 26/52 38/50 7.5 % 0.66 [ 0.48, 0.90 ]
Korkmaz 2007 4/36 7/33 1.4 % 0.52 [ 0.17, 1.63 ]
Sevastiadou 2011 11/51 26/50 5.1 % 0.41 [ 0.23, 0.75 ]
Pawlik 2012 1/50 4/56 0.7 % 0.28 [ 0.03, 2.42 ]
Subtotal (95% CI) 538 557 39.4 % 0.76 [ 0.64, 0.89 ]
Total events: 152 (Glutamine), 207 (Control)
Heterogeneity: Chi2 = 11.27, df = 5 (P = 0.05); I2 =56%
Test for overall effect: Z = 3.31 (P = 0.00092)
2 Parenteral supplementation
Lacey 1996 9/22 7/21 1.4 % 1.23 [ 0.56, 2.69 ]
Thompson 2003 5/17 7/18 1.3 % 0.76 [ 0.30, 1.93 ]
Poindexter 2004 301/721 273/712 52.9 % 1.09 [ 0.96, 1.24 ]
Bober-Olesi ska 2005 7/25 11/30 1.9 % 0.76 [ 0.35, 1.67 ]
Mohamad Ikram 2011 14/76 16/78 3.0 % 0.90 [ 0.47, 1.71 ]
Subtotal (95% CI) 861 859 60.6 % 1.06 [ 0.94, 1.20 ]
Total events: 336 (Glutamine), 314 (Control)
Heterogeneity: Chi2 = 1.71, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 1399 1416 100.0 % 0.94 [ 0.86, 1.04 ]
Total events: 488 (Glutamine), 521 (Control)
Heterogeneity: Chi2 = 23.62, df = 10 (P = 0.01); I2 =58%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 10.75, df = 1 (P = 0.00), I2 =91%
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Analysis 1.4. Comparison 1 Glutamine supplementation versus no supplementation, Outcome 4
Necrotising enterocolitis.
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 1 Glutamine supplementation versus no supplementation
Outcome: 4 Necrotising enterocolitis
Study or subgroup Glutamine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Enteral supplementation
Lacey 1996 2/38 2/39 1.5 % 1.03 [ 0.15, 6.92 ]
Neu 1997 4/35 6/33 4.6 % 0.63 [ 0.19, 2.03 ]
Vaughn 2003 27/314 24/335 17.1 % 1.20 [ 0.71, 2.03 ]
van den Berg 2005 2/52 2/50 1.5 % 0.96 [ 0.14, 6.57 ]
Korkmaz 2007 1/36 2/33 1.5 % 0.46 [ 0.04, 4.82 ]
Sevastiadou 2011 1/51 14/50 10.4 % 0.07 [ 0.01, 0.51 ]
Pawlik 2012 1/50 4/56 2.8 % 0.28 [ 0.03, 2.42 ]
Subtotal (95% CI) 576 596 39.3 % 0.73 [ 0.49, 1.08 ]
Total events: 38 (Glutamine), 54 (Control)
Heterogeneity: Chi2 = 9.95, df = 6 (P = 0.13); I2 =40%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Parenteral supplementation
Thompson 2003 0/17 0/18 Not estimable
Poindexter 2004 69/721 68/712 50.4 % 1.00 [ 0.73, 1.38 ]
Bober-Olesi ska 2005 0/25 5/30 3.7 % 0.11 [ 0.01, 1.87 ]
Mohamad Ikram 2011 5/76 9/78 6.5 % 0.57 [ 0.20, 1.62 ]
Subtotal (95% CI) 839 838 60.7 % 0.90 [ 0.67, 1.22 ]
Total events: 74 (Glutamine), 82 (Control)
Heterogeneity: Chi2 = 3.29, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 0.68 (P = 0.49)
Total (95% CI) 1415 1434 100.0 % 0.83 [ 0.66, 1.06 ]
Total events: 112 (Glutamine), 136 (Control)
Heterogeneity: Chi2 = 13.08, df = 9 (P = 0.16); I2 =31%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 0.73, df = 1 (P = 0.39), I2 =0.0%
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Analysis 1.5. Comparison 1 Glutamine supplementation versus no supplementation, Outcome 5 Rate of
weight gain (g/day).
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 1 Glutamine supplementation versus no supplementation
Outcome: 5 Rate of weight gain (g/day)
Study or subgroup Glutamine Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Enteral supplementation
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Parenteral supplementation
Lacey 1996 22 15 (5) 22 15 (5) 46.2 % 0.0 [ -2.95, 2.95 ]
Thompson 2003 12 19.1 (2.9) 16 16.4 (5.8) 37.4 % 2.70 [ -0.58, 5.98 ]
Wang 2010 13 13.4 (6.4) 15 16 (7) 16.4 % -2.60 [ -7.57, 2.37 ]
Subtotal (95% CI) 47 53 100.0 % 0.59 [ -1.42, 2.59 ]
Heterogeneity: Chi2 = 3.33, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 47 53 100.0 % 0.59 [ -1.42, 2.59 ]
Heterogeneity: Chi2 = 3.33, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Glutamine supplementation versus no supplementation, Outcome 6 Time to
full enteral nutrition (days).
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 1 Glutamine supplementation versus no supplementation
Outcome: 6 Time to full enteral nutrition (days)
Study or subgroup Glutamine Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Enteral supplementation
Korkmaz 2007 36 12.3 (7.2) 33 14.5 (8.7) 10.1 % -2.20 [ -5.99, 1.59 ]
van den Berg 2005 52 13.1 (6.1) 50 16 (9.1) 15.9 % -2.90 [ -5.92, 0.12 ]
Subtotal (95% CI) 88 83 25.9 % -2.63 [ -4.99, -0.27 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
2 Parenteral supplementation
Thompson 2003 12 15.7 (6.5) 16 26.3 (14.9) 2.2 % -10.60 [ -18.77, -2.43 ]
Wang 2010 13 20.2 (6.4) 15 21.3 (8.9) 4.5 % -1.10 [ -6.79, 4.59 ]
Lacey 1996 22 8.3 (5) 22 10.7 (7.4) 10.4 % -2.40 [ -6.13, 1.33 ]
Poindexter 2004 588 34.8 (20.4) 581 35.1 (21.2) 25.4 % -0.30 [ -2.69, 2.09 ]
Mohamad Ikram 2011 76 8.55 (6.06) 78 9.79 (7.41) 31.7 % -1.24 [ -3.38, 0.90 ]
Subtotal (95% CI) 711 712 74.1 % -1.35 [ -2.74, 0.05 ]
Heterogeneity: Chi2 = 5.98, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 1.89 (P = 0.059)
Total (95% CI) 799 795 100.0 % -1.68 [ -2.88, -0.48 ]
Heterogeneity: Chi2 = 6.91, df = 6 (P = 0.33); I2 =13%
Test for overall effect: Z = 2.74 (P = 0.0062)
Test for subgroup differences: Chi2 = 0.84, df = 1 (P = 0.36), I2 =0.0%
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Analysis 1.7. Comparison 1 Glutamine supplementation versus no supplementation, Outcome 7 Duration
of hospital stay (days).
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 1 Glutamine supplementation versus no supplementation
Outcome: 7 Duration of hospital stay (days)
Study or subgroup Glutamine Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Enteral supplementation
van den Berg 2005 45 57 (37.8) 46 65 (30.5) 3.2 % -8.00 [ -22.13, 6.13 ]
Korkmaz 2007 36 28.9 (23.9) 33 30.3 (21.1) 5.7 % -1.40 [ -12.02, 9.22 ]
Vaughn 2003 286 74.6 (30.8) 307 75.1 (29.8) 27.2 % -0.50 [ -5.38, 4.38 ]
Subtotal (95% CI) 367 386 36.2 % -1.32 [ -5.55, 2.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Parenteral supplementation
Thompson 2003 12 92.6 (47.1) 16 85.4 (33.2) 0.7 % 7.20 [ -24.02, 38.42 ]
Lacey 1996 22 88 (21) 22 92 (25) 3.5 % -4.00 [ -17.64, 9.64 ]
Wang 2010 13 48.7 (11.4) 15 48.3 (13.8) 7.4 % 0.40 [ -8.94, 9.74 ]
Poindexter 2004 597 99.9 (48.7) 585 98.1 (43.7) 23.3 % 1.80 [ -3.47, 7.07 ]
Mohamad Ikram 2011 70 13.88 (12.48) 69 16.4 (15.78) 28.9 % -2.52 [ -7.25, 2.21 ]
Subtotal (95% CI) 714 707 63.8 % -0.58 [ -3.77, 2.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.95, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 1081 1093 100.0 % -0.85 [ -3.39, 1.70 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.99, df = 7 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 2.1. Comparison 2 Trials in low- and middle-income countries, Outcome 1 Death prior to hospital
discharge.
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 2 Trials in low- and middle-income countries
Outcome: 1 Death prior to hospital discharge
Study or subgroup Glutamine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wang 2010 0/13 0/15 Not estimable
Korkmaz 2007 3/36 2/33 19.0 % 1.38 [ 0.24, 7.72 ]
Mohamad Ikram 2011 6/76 9/78 81.0 % 0.68 [ 0.26, 1.83 ]
Total (95% CI) 125 126 100.0 % 0.82 [ 0.35, 1.90 ]
Total events: 9 (Glutamine), 11 (Control)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Trials in low- and middle-income countries, Outcome 2 Invasive infection.
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 2 Trials in low- and middle-income countries
Outcome: 2 Invasive infection
Study or subgroup Glutamine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Korkmaz 2007 4/36 7/33 31.6 % 0.52 [ 0.17, 1.63 ]
Mohamad Ikram 2011 14/76 16/78 68.4 % 0.90 [ 0.47, 1.71 ]
Total (95% CI) 112 111 100.0 % 0.78 [ 0.45, 1.36 ]
Total events: 18 (Glutamine), 23 (Control)
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Trials in low- and middle-income countries, Outcome 3 Necrotising
enterocolitis.
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 2 Trials in low- and middle-income countries
Outcome: 3 Necrotising enterocolitis
Study or subgroup Glutamine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Korkmaz 2007 1/36 2/33 19.0 % 0.46 [ 0.04, 4.82 ]
Mohamad Ikram 2011 5/76 9/78 81.0 % 0.57 [ 0.20, 1.62 ]
Total (95% CI) 112 111 100.0 % 0.55 [ 0.21, 1.43 ]
Total events: 6 (Glutamine), 11 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Trials in low- and middle-income countries, Outcome 4 Rate of weight gain
(g/day).
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 2 Trials in low- and middle-income countries
Outcome: 4 Rate of weight gain (g/day)
Study or subgroup Glutamine Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wang 2010 13 13.4 (6.4) 15 16 (7) 100.0 % -2.60 [ -7.57, 2.37 ]
Total (95% CI) 13 15 100.0 % -2.60 [ -7.57, 2.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Trials in low- and middle-income countries, Outcome 5 Time to full enteral
nutrition (days).
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 2 Trials in low- and middle-income countries
Outcome: 5 Time to full enteral nutrition (days)
Study or subgroup Glutamine Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Korkmaz 2007 36 12.3 (7.2) 33 14.5 (8.7) 21.8 % -2.20 [ -5.99, 1.59 ]
Mohamad Ikram 2011 76 8.55 (6.06) 78 9.79 (7.41) 68.6 % -1.24 [ -3.38, 0.90 ]
Wang 2010 13 20.2 (6.4) 15 21.3 (8.9) 9.7 % -1.10 [ -6.79, 4.59 ]
Total (95% CI) 125 126 100.0 % -1.44 [ -3.20, 0.33 ]
Heterogeneity: Chi2 = 0.20, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Trials in low- and middle-income countries, Outcome 6 Duration of hospital
stay (days).
Review: Glutamine supplementation to prevent morbidity and mortality in preterm infants
Comparison: 2 Trials in low- and middle-income countries
Outcome: 6 Duration of hospital stay (days)
Study or subgroup Glutamine Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Korkmaz 2007 36 28.9 (23.9) 33 30.3 (21.1) 13.6 % -1.40 [ -12.02, 9.22 ]
Mohamad Ikram 2011 70 13.88 (12.48) 69 16.4 (15.78) 68.7 % -2.52 [ -7.25, 2.21 ]
Wang 2010 13 48.7 (11.4) 15 48.3 (13.8) 17.7 % 0.40 [ -8.94, 9.74 ]
Total (95% CI) 119 117 100.0 % -1.85 [ -5.77, 2.07 ]
Heterogeneity: Chi2 = 0.31, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Electronic search strategy
Database searches
Cochrane Central Register of Controlled Trials (CENTRAL)
Wiley http://onlinelibrary.wiley.com/
#1 MeSH descriptor: [Infant, Newborn] explode all trees
#2 MeSH descriptor: [Premature Birth] this term only
#3 (neonat* or neo next nat*):ti,ab,kw
#4 (newborn* or new next born* or newly next born*):ti,ab,kw
#5 (preterm or preterms or pre next term or pre next terms):ti,ab,kw
#6 (preemie* or premie or premies):ti,ab,kw
#7 (prematur* near/3 (birth* or born or deliver*)):ti,ab,kw
#8 (low near/3 (birthweight* or birth next weight*)):ti,ab,kw
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#9 (lbw or vlbw or elbw):ti,ab,kw
#10 infan*:ti,ab,kw
#11 (baby or babies):ti,ab,kw
#12 MeSH descriptor: [Enterocolitis, Necrotizing] this term only
#13 enterocolitis:ti,ab,kw
#14 NEC:ti,ab,kw
#15 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 MeSH descriptor: [Glutamine] this term only
#17 glutam*:ti,ab,kw
#18 levoglutam*:ti,ab,kw
#19 #16 or #17 or #18
#20 #15 and #19
#21 #15 and #19 in Trials
#22 #15 and #19 Publication Year from 2007 to 2015, in Trials
Key
MeSH descriptor = indexing term (MeSH heading)
* = truncation
:ti,ab,kw = terms in either title or abstract or keyword ﬁelds
near/3 = terms within three words of each other (any order)
next = terms are next to each other
EMBASE
OvidSP http://ovidsp.ovid.com/
A search strategy developed by Lefebvre 2008 to identify randomised trials in EMBASE was used to limit retrieval to clinical trials
(lines 22-36).
1 exp infant/
2 prematurity/
3 premature labor/
4 exp low birth weight/
5 (neonat$ or neo nat$).ti,ab.
6 (newborn$ or new born$ or newly born$).ti,ab.
7 (preterm or preterms or pre term or pre terms).ti,ab.
8 (preemie$ or premie or premies).ti,ab.
9 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab.
10 (low adj3 (birthweight$ or birth weight$)).ti,ab.
11 (lbw or vlbw or elbw).ti,ab.
12 infan$.ti,ab.
13 (baby or babies).ti,ab.
14 necrotizing enterocolitis/
15 enterocolitis.ti,ab.
16 NEC.ti,ab.
17 or/1-16
18 glutamine/
19 glutam$.ti,ab.
20 levoglutam$.ti,ab.
21 18 or 19 or 20
22 random$.ti,ab.
23 factorial$.ti,ab.
24 crossover$.ti,ab.
25 cross-over$.ti,ab.
26 placebo$.ti,ab.
27 (doubl$ adj blind$).ti,ab.
28 (singl$ adj blind$).ti,ab.
29 assign$.ti,ab.
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30 allocat$.ti,ab.
31 volunteer$.ti,ab.
32 Crossover Procedure/
33 double blind procedure/
34 Randomized Controlled Trial/
35 single blind procedure/
36 or/22-35
37 17 and 21 and 36
38 animal/
39 exp animal experiment/
40 Nonhuman/
41 (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or cats or bovine or sheep).ti,ab,sh.
42 38 or 39 or 40 or 41
43 exp human/
44 human experiment/
45 43 or 44
46 42 not (42 and 45)
47 37 not 46
48 limit 47 to em
Key:
/ = indexing term (EMTREE heading)
$ = truncation
.ti,ab. = terms in either title or abstract ﬁelds
adj3 = terms within three words of each other (any order)
.sh.= subject heading ﬁeld
.em. = entry date - date added to database
Maternity and Infant Care
OvidSP http://ovidsp.ovid.com/
1 Infant.de.
2 Infant - newborn.de.
3 Infant - premature.de.
4 infant - very premature.de.
5 Infant - low birth weight.de.
6 Infant - very low birth weight.de.
7 Premature birth.de.
8 Infant - small for gestational age.de.
9 (neonat$ or neo nat$).ti,ab.
10 (newborn$ or new born$ or newly born$).ti,ab.
11 (preterm or preterms or pre term or pre terms).ti,ab.
12 (preemie$ or premie or premies).ti,ab.
13 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab.
14 (low adj3 (birthweight$ or birth weight$)).ti,ab.
15 (lbw or vlbw or elbw).ti,ab.
16 infan$.ti,ab.
17 (baby or babies).ti,ab.
18 Enterocolitis.de.
19 enterocolitis.ti,ab.
20 NEC.ti,ab.
21 or/1-20
22 Glutamine.de.
23 glutam$.ti,ab.
24 levoglutam$.ti,ab.
25 22 or 23 or 24
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26 21 and 25
27 limit 26 to yr=“2007 -Current”
Key
.de. = indexing term
$ = truncation
.ti,ab. = terms in either title or abstract ﬁelds
adj3 = terms within three words of each other (any order)
yr = year published
MEDLINE
OvidSP http://ovidsp.ovid.com/
The Cochrane highly sensitive search strategy for identifying randomized trials in MEDLINE (sensitivity-maximizing version) was
used to limit retrieval to clinical trials (lines 21-31) (Lefebvre 2011).
1 exp Infant, Newborn/
2 Premature Birth/
3 (neonat$ or neo nat$).ti,ab.
4 (newborn$ or new born$ or newly born$).ti,ab.
5 (preterm or preterms or pre term or pre terms).ti,ab.
6 (preemie$ or premie or premies).ti,ab.
7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab.
8 (low adj3 (birthweight$ or birth weight$)).ti,ab.
9 (lbw or vlbw or elbw).ti,ab.
10 infan$.ti,ab.
11 (baby or babies).ti,ab.
12 Enterocolitis, Necrotizing/
13 enterocolitis.ti,ab.
14 NEC.ti,ab.
15 or/1-14
16 Glutamine/
17 glutam$.ti,ab.
18 levoglutam$.ti,ab.
19 16 or 17 or 18
20 15 and 19
21 randomized controlled trial.pt.
22 controlled clinical trial.pt.
23 randomized.ab.
24 placebo.ab.
25 drug therapy.fs.
26 randomly.ab.
27 trial.ab.
28 groups.ab.
29 or/21-28
30 exp animals/ not humans.sh.
31 29 not 30
32 15 and 19 and 31
33 limit 32 to ed=20111101-20140911
Key
/ = indexing term (MeSH heading)
exp = exploded MeSH heading
$ = truncation
.ti,ab. = terms in either title or abstract ﬁelds
adj3 = terms within three words of each other (any order)
.pt. = publication type
.fs. = ﬂoating subheading
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.sh.= subject heading
.ed. = entry date - date added to the database
MEDLINE In-Process & Other Non-Indexed Citations
OvidSP http://ovidsp.ovid.com/
1 exp Infant, Newborn/
2 Premature Birth/
3 (neonat$ or neo nat$).ti,ab.
4 (newborn$ or new born$ or newly born$).ti,ab.
5 (preterm or preterms or pre term or pre terms).ti,ab.
6 (preemie$ or premie or premies).ti,ab.
7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab.
8 (low adj3 (birthweight$ or birth weight$)).ti,ab.
9 (lbw or vlbw or elbw).ti,ab.
10 infan$.ti,ab.
11 (baby or babies).ti,ab.
12 Enterocolitis, Necrotizing/
13 enterocolitis.ti,ab.
14 NEC.ti,ab.
15 or/1-14
16 Glutamine/
17 glutam$.ti,ab.
18 levoglutam$.ti,ab.
19 16 or 17 or 18
20 15 and 19
21 limit 20 to ed=20111101-20140918
Key
/ = indexing term (MeSH heading)
exp = exploded MeSH heading
$ = truncation
.ti,ab. = terms in either title or abstract ﬁelds
adj3 = terms within three words of each other (any order)
ed = entry date - date added to the database
PubMed
http://www.ncbi.nlm.nih.gov/pubmed/
The Cochrane highly sensitive search strategy for identifying randomized trials in PubMed (sensitivity-maximizing version) was used
to limit retrieval to clinical trials (Lefebvre 2011).
Search ((((((((((((((((((((((“Infant, Newborn”[Mesh])) OR (“Premature Birth”[Mesh])) OR (((neonat*[Title/Abstract]) OR neo
nat*[Title/Abstract]) OR neo-nat*[Title/Abstract])) OR (((((newborn*[Title/Abstract]) OR new born*[Title/Abstract]) OR new-
born*[Title/Abstract]) OR newly born*[Title/Abstract]) OR newly-born*[Title/Abstract])) OR ((((((preterm[Title/Abstract]) OR
preterms[Title/Abstract]) OR pre term[Title/Abstract]) OR pre-term[Title/Abstract]) OR pre terms[Title/Abstract]) OR pre-
terms[Title/Abstract])) OR (((preemie*[Title/Abstract]) OR premie[Title/Abstract]) OR premies[Title/Abstract])) OR ((pre-
matur*[Title/Abstract]) AND birth*[Title/Abstract])) OR ((prematur*[Title/Abstract]) AND born[Title/Abstract])) OR ((pre-
matur*[Title/Abstract]) AND deliver*[Title/Abstract])) OR ((low[Title/Abstract]) AND birthweight*[Title/Abstract])) OR
((low[Title/Abstract]) AND birth weight*[Title/Abstract])) OR ((low[Title/Abstract]) AND birth-weight*[Title/Abstract])) OR
(((lbw[Title/Abstract]) OR vlbw[Title/Abstract]) OR elbw[Title/Abstract])) OR (infan*[Title/Abstract])) OR ((baby[Title/Abstract])
OR babies[Title/Abstract])) OR (“Enterocolitis, Necrotizing”[Mesh:noexp]) OR (enterocolitis[Title/Abstract]) OR (NEC[Title/Ab-
stract]))) AND (((levoglutam*[Title/Abstract]) OR glutam*[Title/Abstract]) OR “Glutamine”[Mesh:noexp]))) AND (((((((((((ran-
domized controlled trial[Publication Type])) OR (controlled clinical trial[Publication Type])) OR (randomized[Title/Abstract])) OR
(placebo[Title/Abstract])) OR (drug therapy[MeSH Subheading])) OR (randomly[Title/Abstract])) OR (trial[Title/Abstract])) OR
(groups[Title/Abstract]))) NOT (animals[mh] NOT humans[mh])))) AND (“2011/11/01”[Date - Entrez] : “3000”[Date - Entrez])
Key
[Mesh] = exploded Medical Subject heading (MeSH)
[mh] = exploded MeSH
50Glutamine supplementation to prevent morbidity and mortality in preterm infants (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Mesh:noexp] = MeSH not exploded
* = truncation
[Title/Abstract] = terms in either title or abstract ﬁelds
[Date - Entrez] = entry date - date added to the database
Trial register searches
Clinical Trials.gov
http://clinicaltrials.gov/
Glutamine AND (infant OR infants OR newborn OR newborns OR premature OR prematurity OR neonate OR neonates OR
neonatal OR pretermOR preterms OR preemie OR preemies OR premie OR premies OR birthweight OR baby OR babies) | received
on or after 11/01/2011 | updated on or after 11/01/2011
1 study found for: Glutamine AND (NEC OR enterocolitis) | received on or after 11/01/2011 | updated on or after 11/01/2011
12 studies found for: “Glutamine” | Child | received on or after 11/01/2011 | updated on or after 11/01/2011
metaRegister of Controlled Trials (mRCT)
http://www.controlled-trials.com/mrct/searchform
(Glutamine AND (infant OR infants ORnewborn ORnewborns ORpremature ORprematurity ORneonate ORneonates or neonatal
OR preterm OR preterms OR preemie OR preemies OR premie OR premies OR birthweight OR baby OR babies OR enterocolitis
or NEC))
WHO International Clinical Trials Registry Platform
http://apps.who.int/trialsearch/AdvSearch.aspx
1. glutam* in title, clinical trials in children
2. glutam* in intervention ﬁeld, clinical trials in children
F E E D B A C K
Hans Van Rostenberghe Feedback and Review Author Response, 11 September 2007
Summary
Glutamine has been shown to be a very useful additive to parenteral nutrition in adults. For neonates, it may be useful to consider
the potential differences between developed and developing nations. Differences in nutritional status of the mothers may result in less
available glutamine for the neonate. Furthermore infection rates tend to be a lot higher in settings of developing nations. Large trials
in a developing nation may be still very useful to perform.
Reply
Thank you for highlighting that the ﬁndings of studies undertaken in high-income countries may not be wholly applicable to infants in
low-and middle-income countries. We have pre-speciﬁed subgroup analyses of studies undertaken in low- and middle-income countries
in the 2011 update of this review.
Contributors
Thirimon Moe Byrne, Jennifer VE Wagner, William McGuire.
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WH A T ’ S N E W
Last assessed as up-to-date: 18 December 2015.
Date Event Description
18 April 2016 Amended Minor edit
7 January 2016 New citation required but conclusions have not
changed
Inclusion of a new trial and new follow-up data did
not change the conclusion
18 December 2015 New search has been performed This updates the review “Glutamine supplementation
to preventmorbidity andmortality in preterm infants”
published in the Cochrane Database of Systematic Re-
views (Moe-Byrne 2012).
Updated search identiﬁed one new trial and one pub-
lication of follow-up data for inclusion in this review
H I S T O R Y
Protocol ﬁrst published: Issue 2, 1999
Review ﬁrst published: Issue 2, 1999
Date Event Description
30 November 2011 New citation required and conclusions have changed Further evaluation of routine parenteral glutamine
supplementation in preterm infants is unlikely to be
considered a research priority, but the inclusion of new
trial data in this update provides some support for fur-
ther trials of enteral glutamine supplementation to be
undertaken
New authorship.
30 November 2011 New search has been performed This updates the review “Glutamine supplementation
to preventmorbidity andmortality in preterm infants”
published in the Cochrane Database of Systematic Re-
views (Tubman 2008).
Updated search identiﬁed four new trials for inclusion
in this review
30 November 2011 Feedback has been incorporated Feedback on 2008 version of review byHans Von Ros-
tenberghe (Feedback 1) incorporated by adding an ad-
ditional subgroup analysis.
8 May 2008 Amended Converted to new review format.
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(Continued)
8 May 2008 Feedback has been incorporated Feedback incorporated
13 November 2007 New search has been performed This updates the existing review of “Glutamine sup-
plementation to prevent morbidity and mortality in
preterm infants” published in The Cochrane Library,
Issue 1, 2005 (Tubman 2005).
One new trial was identiﬁed for this update (Bober-
Olesinska 2005). Inclusion of data from this trial did
not change the main ﬁndings or conclusions of this
review
C O N T R I B U T I O N S O F A U T H O R S
JVEW, WM and TMB searched and screened the studies for inclusion, assessed the methodological quality of the trials and extracted
and entered the relevant information and data from each included study independently. WM and JVEW completed the ﬁnal review.
D E C L A R A T I O N S O F I N T E R E S T
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
None.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Dietary Supplements; ∗Infant Mortality; ∗Infant Nutritional Physiological Phenomena; ∗Infant, Premature; Glutamine
[∗administration & dosage]; Infant, Very Low Birth Weight; Randomized Controlled Trials as Topic
MeSH check words
Humans; Infant, Newborn
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